Illumina
Yahoo Finance • 3 months ago
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswell will step down as General Counsel and... Full story
Yahoo Finance • 3 months ago
Shareholders in Illumina (NASDAQ:ILMN) are in the red if they invested three years ago
While not a mind-blowing move, it is good to see that the Illumina, Inc. (NASDAQ:ILMN) share price has gained 23% in the last three months. But that doesn't change the fact that the returns over the last three years have been disappointing... Full story
Yahoo Finance • 3 months ago
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
Amid rising agricultural complexity and the push for sustainability, genomics is at the forefront of innovation in breeding practices. SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC... Full story
Yahoo Finance • 4 months ago
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances access to localized precision oncology f... Full story
Yahoo Finance • 4 months ago
Illumina, Inc. (ILMN): Is This Cheap Robotic Stock a Good Buy Right Now?
We recently compiled a list of the 10 Cheap Robotics Stocks To Buy.In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other cheap robotic stocks. The progress of Western civilization is b... Full story
Yahoo Finance • 8 months ago
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencing Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recent literature review, published in the... Full story
Yahoo Finance • 9 months ago
14 Best Medical Device Stocks To Buy Now
In this article, we will discuss the 14 Best Medical Device Stocks To Buy Now. You can skip our detailed analysis of the Medical Device Industry and go directly to the 5 Best Medical Device Stocks To Buy Now. The healthcare sector relies... Full story
Yahoo Finance • 9 months ago
10 Biggest Stocks Targeted By Activist Investors Right Now
In this article, we're going to take a look at 10 biggest stocks targeted by activist investors right now. You can skip ahead and take a look at more stocks that made our list by jumping straight to the top 5 biggest stocks targeted by act... Full story
Yahoo Finance • 10 months ago
Do You Believe in the Growth Prospects of Illumina (ILMN)?
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The Russell 100... Full story
Yahoo Finance • 10 months ago
Illumina Inc CEO Jacob Thaysen Acquires 7,330 Shares
On February 22, 2024, Jacob Thaysen, CEO of Illumina Inc (NASDAQ:ILMN), made a significant insider purchase, acquiring 7,330 shares of the company's stock, as reported in a recent SEC Filing. This transaction has caught the attention of ma... Full story
Yahoo Finance • 10 months ago
15 Best Shareholder Activism Law Firms
In this article, we discuss the 15 Best Shareholder Activism Law Firms. If you would like to discuss our detailed discussion and analysis of the shareholder activism space as of 2024, you can skip it and go directly to 5 Best Shareholder A... Full story
Yahoo Finance • 10 months ago
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments... Full story
Yahoo Finance • 11 months ago
Here’s How the New AI Algorithm Helps Illumina (ILMN)
Ensemble Capital Management, an investment management company, released its fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund saw exceptionally excellent absolute and relative performance in the fourt... Full story
Yahoo Finance • last year
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 Presentati... Full story
Yahoo Finance • last year
Heard on the Street: Illumina Nears the End of Its Painful Grail Saga
Grail’s screening test, called Galleri, could one day help save countless lives by catching cancer in the bloodstream early. After losing in court [against the Federal Trade Commission](https://www.wsj.com/health/healthcare/court-sides-wit... Full story
Yahoo Finance • last year
PRESS DIGEST- Wall Street Journal - Dec 18
Dec 18 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Gene-sequencing company Illumina said on Sunday it will divest itself of canc... Full story
Yahoo Finance • last year
Illumina To Sell Grail After U.S. Antitrust Ruling
Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws, Continue reading... Full story
Yahoo Finance • last year
UPDATE 2-Illumina to divest cancer test maker Grail after antitrust battles
(Adds background in paragraphs 4, 8-9, 12) Dec 17 (Reuters) - Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for mor... Full story
Yahoo Finance • last year
Illumina to divest cancer test maker Grail after antitrust battles
(Reuters) -Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from ac... Full story
Yahoo Finance • last year
Illumina Announces Decision to Divest GRAIL
SAN DIEGO, Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the Eu... Full story
